Research progress of nucleostemin signaling pathway in tumorigenesis and development

Abstract

Abstract: Silencing nucleostemin (NS) can activate the p53 pathway and p53 inhibit proliferation of the tumor cell through the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (PKB or AKT)/ mammalian target of rapamycin (mTOR) signal pathway. Low expression of NS also inhibits the PI3K/AKT/mTOR signal pathway through a non-p53 pathway. Inhibition of p53 activates the Wnt/β-catenin signal pathway. High expression of NS also activates the Wnt/β-catenin signal pathway. Over-expression of c-Myc increases NS expression and inhibits p53 expression,which may promote cell proliferation.

Key words: nucleostemin(NS), gene, protein, signal pathway

CLC Number:

R730.231

HE Zhen-hua, SHEN Fu-hui, ZENG Fan-gang, LIU Qian-lin, YUAN Jing-min. Research progress of nucleostemin signaling pathway in tumorigenesis and development[J]. Basic & Clinical Medicine, 2020, 40(4): 547-551.

References

[1]Wang J, Wang L, Ji Q, et al. Knockdown of nucleoste-min in an ovarian cancer SKOV-3 cell line and its effects on cell malignancy[J]. Biochem Biophys Res Commun, 2017, 487: 262-267.
[2]Su H, Kang Q, Wang H, et al. Changes in expression of p53 and inflammatory factors in patients with ulcerative colitis[J]. Exp Ther Med, 2019, 17: 2451-2456.
[3]Wurz RP, Cee VJ. Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors[J]. J Med Chem, 2019, 62: 445-447.
[4]Hua L, Hu B, Yan D, et al. Upregulated expression of nucleostemin/GNL3 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma[J]. Pathol Res Pract, 2017, 213: 688-697.
[5]Sami MM, Hachim MY, Hachim IY, et al. Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients' outcome: a STROBE-compliant article[J]. Medicine (Baltimore), 2019, 98: e14744. doi: 10.1097/MD.0000000000014744.
[6]Wang S, Zhu M, Wang Q, et al. Publisher Correction: alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling[J]. Cell Death Dis, 2019, 10: 214. doi: 10.1038/s41419-018-1292-4.
[7]贾宇, 魏园玉, 李曌博, 等. HL-60细胞Nucleostemin表达下调对PI3K/AKT/mTOR信号通路相关蛋白的影响[J]. 中国实验血液学杂志, 2017, 25: 1592-1596.
[8]Li F, Miao L, Xue T, et al. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells[J]. J Exp Clin Cancer Res, 2019, 38: 414. doi: 10.1186/s13046-019-1404-8.
[9]Bao Z, Wang Y, Yang L, et al. Nucleostemin promotes the proliferation of human glioma via Wnt/beta-Catenin pathway[J]. Neuropathology, 2016, 36: 237-249.
[10]Silva-Garcia O, Valdez-Alarcon JJ, Baizabal-Aguirre VM. Wnt/beta-catenin signaling as a molecular target by pathogenic bacteria[J]. Front Immunol, 2019, 10: 2135. doi: 10.3389/fimmu.2019.02135.
[11]Li J, Zhang Z, Wang L, et al. The oncogenic role of Wnt10a in colorectal cancer through activation of canonical Wnt/β-catenin signaling[J]. Oncol Lett, 2019, 17: 3657-3664.
[12]Sasaki T, Kuniyasu H, Luo Y, et al. Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells[J]. Cancer Sci, 2012, 103: 1165-1171.
[13]Prieto JD, Alvarez M, Hierro MI, et al. Beta-catenin and p53 expression in topographic compartments of colorectal cancer and its prognostic value following surgery[J]. Ann Diagn Pathol, 2017, 31: 1-8.
[14]Alaee M, Nool K, Pasdar M. Plakoglobin restores tumor suppressor activity of p53(R175H) mutant by sequester-ing the oncogenic potential of beta-catenin[J]. Cancer Sci, 2018, 109: 1876-1888.
[15]Keremu A, Maimaiti X, Aimaiti A, et al. NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/beta-catenin signaling[J]. Am J Cancer Res, 2017, 7: 565-573.
[16]张昌文. ROCK-c-Myc通路促进肿瘤增殖的分子机制研究[D]. 天津:天津医科大学, 2012: 33-34.
[17]Zwolinska AK, Heagle Whiting A, Beekman C, et al. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency[J]. Oncogene, 2012, 31: 3311-3321.
[18]齐士勇. NS调节核糖体蛋白合成促进前列腺癌细胞增殖机制的研究[D]. 天津:天津医科大学, 2015: 93-88.
[19]Yuan F, Liu L, Lei Y, et al. p53 inhibits the upregula-tion of sirtuin 1 expression induced by c-Myc[J]. Oncol Lett, 2017, 14: 4396-4402.
[20]Zhao X, Petrashen AP, Sanders JA, et al. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice[J]. Aging Cell, 2019, 18: e12947. doi: 10.1111/acel.12947.
[21]Liu R, Li Y, Tian L, et al. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating beta-catenin/c-Myc signaling in human hepatocellular carcinoma[J]. Cancer Lett, 2019, 443: 34-46.
[22]Zhang S, Xu J, Wang H, et al. Downregulation of long noncoding RNA LINC00460 expression suppresses tumor growth in vitro and in vivo in gastric cancer[J]. Cancer Biomark, 2019, 24: 429-437.
[23]Wang Q, Zhou Y, Rychahou P, et al. Deptor is a novel target of Wnt/beta-catenin/c-Myc and contributes to colorectal cancer cell crowth[J]. Cancer Res, 2018, 78: 3163-3175.